The Nalu Bio Team
Nalu Bio is a world-class team of industry-leading experts dedicated to bringing scientific rigor to the production and discovery of the next generation of cannabinoid products.
CEO & Co-founder
Entrepreneur with 20 years of healthcare experience with a passion for building companies at the intersection of science and technology–epigenomics, diagnostics, digital health, and eye tracking. Focused on commercializing new products and technologies within wellness and health. Mother of two boys, raised in Hawaii, and a Crossfitter. BS in biology from Brown University.
"I'm committed to building a world-class team that will deliver high-quality cannabinoid-derived ingredients that consumers and people living with chronic pain can trust."
Chief Technology Officer
Serial CTO with 25+ years of experience leading science, technology, and innovation for global leaders in Food and Nutrition. His experience and expertise span food, nutrition, operations, process scale-up, clinical trials, regulatory and quality. He has worked for large consumer packaged good companies and chemical ingredient companies including Nestle, Abbott Nutrition, Pharmavite—The Nature’s Bounty Company, Chromadex, and the Health & Happiness Group. Matthew has authored 30+ publications and patents and received his BS from Purdue University, his PhD from Cornell, and an Executive MBA from Washington University, St. Louis. Matthew is the father of 3 children, an avid hiker and runner, and a voracious consumer of science journalism and philosophy.
"I'm committed to help consumers, product innovators, and scientific researchers benefit from the full potential of high-quality, consistent, and safe CBD. Our team has worked tirelessly over the last year to develop a novel and scalable cannabinoid chemistry platform that will meet both the quality and quantity demands of a market projected to reach $20B by 2025."
Chief Medical Officer
A world class physician with more than 25+ years of experience in healthcare as a physician and drug development expert. He has served as the Chief Medical Officer and held leading roles at Genentech, BioMarin Pharmaceutical, Chiron, Reneo Pharmaceuticals, Allakos, and Lumena Pharmaceuticals. Developed 30+ drugs in allergy, HIV/AIDS, pulmonary, immunological, cardiovascular, metabolic, and pediatric diseases. Currently a Clinical Professor at Stanford School of Medicine where he sees patients weekly. Received his MD from The National Autonomous University in Mexico City, Residency at University of Texas Health Science Center, and Fellowship at Baylor College of Medicine.
"As a physician, I recognize and am excited about the broad therapeutic potential of CBD. To fully achieve that potential, we urgently need a trustworthy, science-backed, consistently performing CBD product on the market. That's why I'm so enthusiastic about Nalu Bio—to help advance the development of a pure, consistent, medical-grade CBD to advance the treatment of multiple diseases."
Co-founder and Board Member
Serial entrepreneur with 25+ years of healthcare experience. Builds, invests and creates companies within therapeutics, diagnostics, life science tools, digital health, and personalized medicine. Sits on multiple boards and is dedicated to helping social entrepreneurs address the problems of poverty, empower women, and build resilience to climate change. Passion for transformative life science innovations, healthcare solutions, global health, mentorship, and locavore cooking. BA in Chemistry and Ph.D in Pharmacology from Washington University, St. Louis, Missouri.
“Engineering new CBD chemical entities for optimal therapeutic effect has very exciting potential for patients and physicians alike.”
Co-founder and Board Member
Entrepreneur and investor with 15+ years sitting at the intersection of design and business, bringing new products and companies to life for startups and F1000 companies. Expert at incubating, investing, and advising on design and Go-to-Market for early stage startups. Sits on multiple Boards in healthcare, education, and fintech. BA from James Madison University and MBA from Babson College.
“Let's clinically validate what we know about cannabinoids, and then make those benefits available at a global scale, so we can solve a ton of problems and improve people’s lives."
Ken Mackie, MD
Scientific Advisor and Research Partner
Chair and Distinguished Professor in Psychological and Brain Sciences at the Gill Center for Biomolecular Science, Indiana University. Research in neuroscience, regulation of CB1 receptors, regulation of endocannabinoid production, and role of novel cannabinoid receptors. 400 publications with 100+ publications on cannabinoids and the endocannabinoid system, ScB in Engineering, Brown University, MD from Yale University.
“I’m really excited to evaluate how the potency and efficacy of Nalu Bio’s proprietary synthetic cannabinoids—specifically their market-ready CBD—may enable the development of effective non-opioid pain management."
Christopher Dino Beckett, DO
Clinical Advisor and Research Partner
A rural family medicine physician and entrepreneur, Dr. Beckett is known for his innovation and leadership in treating the opioid crisis in West Virginia. He has been named the “National Rural Health Center’s Rural Practitioner of the Year” after being nominated by his peers. He has been instrumental in the treatment of patients suffering addiction in central Appalachia by creating Medically Assisted Treatment Centers. He has led the charge to open a recently closed acute care facility to create a detoxification unit and outpatient treatment facility while creating internships and workforce development for individuals successfully participating in recovery. BA in biology from West Virginia University and DO from West Virginia School of Osteopathic Medicine.
“The challenge of treating intractible pain for the vast number of patients who suffer from it remains a significant challenge for clinicians. I've experienced first hand how the limitations of pain meds can contribute to opioid abuse and addiction. I've had a lot of success with CBD as an opioid-sparing alternative; and Nalu Bio's Ultra-pure CBD is an important advance because it assures the consistency and predictable dose-to-dose performance we need for further research.”
Sam Banister, PhD
A Team Leader in Medicinal Chemistry at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Research on new cannabinoid drugs for epilepsy, neuropathic pain, depression, anxiety, substance abuse, and more. Authored two book chapters on the chemistry of synthetic cannabinoids, 70+ peer-reviewed publications, postdoc at Stanford University, BSc and PhD in Chemistry, University of Sydney.
"Innovative chemistry and rigorous data are crucial for manufacturing complex natural products like cannabinoids at scale. I am very excited that Nalu Bio is raising the standard and working to bring such high quality cannabinoids to the market."
Nalu Bio offers a complimentary 10g sample for product manufacturers interested in testing our Ultra-pure CBD.
Samples are exclusive to industry partners and not for consumers.